A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

Publication | Closed Access

DOI

105

Citations

References

2010

Year

Jean‐Yves Pierga, Suzette Delaloge, Marc Espié, Étienne Brain, Brigitte Sigal‐Zafrani, Marie‐Christine Mathieu, Philippe Bertheau, Jean Marc Guinebretière, M. Spielmann, Alexia Savignoni,

Breast Cancer Research and Treatment

Her2 StatusBreast OncologyMedicinePharmacologyCancer PharmacologyPhase Ii StudyBreast CancerPharmacotherapyPrimary ChemotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology